https://www.selleckchem.com/pr....oducts/apr-246-prima
The majority of patients were converted to transdermal rotigotine (90%). Patients converted to a higher than equivalent dose of rotigotine were more likely to be agitated (p0.05), whilst those converted to a lower than equivalent dose were less likely to develop excess respiratory secretions (p0.05). The prevalence of pain did not differ according to rotigotine dosing. This study highlights for the first time use of anticipatory medications at the end of life in patients with idiopathic Parkinson's disease and the pre
Like
Comment
Share
